FDA's Opioid Regret? Skipping Another Zohydro Meeting, Califf Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency addressed post-marketing concerns raised by advisory committee, Commissioner tells Senate, but should have returned to get panel's blessing.
You may also be interested in...
The Short And Controversial Life Of Zohydro Comes To An End
US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.
Unasked Questions: The Odd Dynamics Of FDA Commissioner Hearings
Is there anything less satisfying than a confirmation hearing for US FDA commissioner? Robert Califf performed very well during his testimony to return to the post, but no one who follows FDA closely likely learned much they did not already know.
Unasked Questions: The Odd Dynamics Of FDA Commissioner Hearings
Is there anything less satisfying than a confirmation hearing for US FDA commissioner? Robert Califf performed very well during his testimony to return to the post, but no one who follows FDA closely likely learned much they did not already know.